Related Experiment Videos
Left ventricular end-diastolic pressure-volume relationships in hypertrophic cardiomyopathy. Changes induced by
Insights
Intravenous verapamil improved left ventricular filling in hypertrophic cardiomyopathy patients. It lowered end-diastolic pressure while increasing end-diastolic volume, benefiting overall cardiac function.
Area of Science:
- Cardiology
- Pharmacology
- Cardiovascular Physiology
Background:
- Hypertrophic cardiomyopathy (HCM) is a complex cardiac condition characterized by abnormal thickening of the heart muscle.
- Impaired left ventricular filling is a common and significant issue in patients with HCM.
- Understanding the acute effects of pharmacological agents on cardiac filling dynamics is crucial for patient management.
Purpose of the Study:
- To assess the acute hemodynamic response to intravenous verapamil in patients diagnosed with hypertrophic cardiomyopathy.
- To evaluate the impact of verapamil on left ventricular end-diastolic pressure and end-diastolic volume index.
- To determine if verapamil improves the pressure-volume relationship during ventricular filling in HCM.
Main Methods:
- A study involving 16 patients with confirmed hypertrophic cardiomyopathy.
- Intravenous administration of verapamil as the intervention.
- Measurement of left ventricular end-diastolic pressure (LVEDP) and left ventricular end-diastolic volume index (LVEDVI) before and after verapamil infusion.
- Analysis of the pressure-volume relationship to assess filling efficiency.
Main Results:
- Verapamil significantly reduced left ventricular end-diastolic pressure from 20 ± 6 to 17 ± 5 mm Hg (p < 0.001).
- Verapamil significantly increased the left ventricular end-diastolic volume index from 82 ± 22 to 91 ± 23 ml/sqm (p < 0.01).
- Improved end-diastolic pressure-volume relationships were observed in 13 out of 16 patients (81%).
Conclusions:
- Intravenous verapamil demonstrates a beneficial acute effect on left ventricular filling conditions in patients with hypertrophic cardiomyopathy.
- The drug effectively augments ventricular filling volume while simultaneously reducing filling pressure.
- These findings suggest verapamil can favorably alter diastolic function in HCM, potentially improving cardiac output and symptoms.
Abstract:
In 16 patients with hypertrophic cardiomyopathy, an acute response of the left ventricular end-diastolic pressure and volume index to intravenously administered verapamil was assessed. Verapamil decreased the left ventricular end-diastolic pressure from 20 +/- 6 to 17 +/- 5 mm Hg(p less than 0.001) and increased the end-diastolic volume index from 82 +/- 22 to 91 +/- 23 ml/sqm (p less than 0.01). In 13 (81 percent) of 16 patients, an improvement of end-diastolic pressure-volume relationships occurred. In hypertrophic cardiomyopathy, intravenous verapamil exerts a beneficial effect on left ventricular filling conditions, producing an augmentation of filling volume at a lower filling pressure.